Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 223

Sort by

Sort Order Select

Journal Articles

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Blood (2025) 145 (17): 1870–1875.

https://doi.org/10.1182/blood.2024026700

Published: 2025

Includes: Supplemental data

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Blood (2024) 144 (Supplement 1): 57.

https://doi.org/10.1182/blood-2024-211685

Published: 2024

Journal Articles

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

Blood (2024) 144 (Supplement 1): 6175.

https://doi.org/10.1182/blood-2024-208911

Published: 2024

Journal Articles

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

M Bakri Hammami, Jeevan Shivakumar, Nina Samuel, Rajvi Gor, Mendel Goldfinger, Noah Kornblum, Lauren Shapiro, Aditi Shastri, Ridhi Gupta, David Levitz, Marina Konopleva, Eric J. Feldman, Kira Gritsman, R. Alejandro Sica, Ioannis Mantzaris, Amit Verma, Dennis L Cooper, Nishi Shah

Blood (2024) 144 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2024-208770

Published: 2024

Journal Articles

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Blood (2024) 144 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2024-201590

Published: 2024

Journal Articles

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew T. Kuykendall, David Sallman, Manish Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2024-198495

Published: 2024

Journal Articles

Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

Blood (2024) 144 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2024-198479

Published: 2024

Journal Articles

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

John X Wei, Mendel Goldfinger, Marina Konopleva, Ioannis Mantzaris, Amit Verma, Eric J. Feldman

Blood (2024) 144 (Supplement 1): 3802.

https://doi.org/10.1182/blood-2024-206488

Published: 2024

Journal Articles

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Guillermo Garcia-Manero, David Sallman, Stefano R Tarantolo, Amit Verma, Stefanie Groepper, Alice Mims, Yasmin Abaza, James P. Dugan, Valle Gomez G De Soria, Gaurav S Choudhary, Maureen Lane, Wanying Zhao, Ashish Jain, Cole Gallagher, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2024-208292

Published: 2024

Journal Articles

Neurotoxicity of Axicabtagene Ciloleucel in an Ethnically Diverse, Real-World Cohort

Elizabeth Zeldin, Samantha J Cheng, Ryann Quinn, Kith Pradhan, Mendel Goldfinger, Ioannis Mantzaris, Nishi Shah, Aditi Shastri, Noah Kornblum, Dennis L Cooper, Ridhi Gupta, Lauren Shapiro, Kira Gritsman, Ahmed Abbasi, Amit Verma, Ira Braunschweig, Katharine McNeill, Mark Milstein, R. Alejandro Sica

Blood (2024) 144 (Supplement 1): 7201.

https://doi.org/10.1182/blood-2024-201715

Published: 2024

Journal Articles

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Blood (2024) 144 (Supplement 1): 4265.5.

https://doi.org/10.1182/blood-2024-208998

Published: 2024

Journal Articles

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Blood (2024) 144 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2024-211956

Published: 2024

Journal Articles

Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

Blood (2024) 144 (Supplement 1): 943.

https://doi.org/10.1182/blood-2024-194127

Published: 2024

Journal Articles

KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

Leah Kravets, Mirca S. Saurty-Seerunghen, Divij Verma, Ariel Fromowitz, Srabani Sahu, Bradley Rockwell, Olivia Sakaguchi, Swathi Narayanagari, Shanisha Gordon Mitchell, Milagros Carbajal, Srinivas Aluri, Jingli Wang, Lindsay Lafave, Marina Konopleva, Anna S. Nam, Amit Verma

Blood (2024) 144 (Supplement 1): 326.

https://doi.org/10.1182/blood-2024-208924

Published: 2024

Journal Articles

Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Norman Fultang, Ashley M Schwab, Ian Johnson, Alexander Grego, Emma Filler, Carly Bachner, Jake Karwoski, Andrew Moore, Ashley Bartilomo, Anjana Agarwal, Olusola Peace Osinubi, Koichi Ito, Sarah Aminov, Srabani Sahu, Amit Verma, Peggy A Scherle, Neha Bhagwat, Diane Heiser

Blood (2024) 144 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2024-208196

Published: 2024

Journal Articles

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Blood (2024) 144 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2024-206160

Published: 2024

Journal Articles

North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist

Eric Liu, Amit Verma, Kith Pradhan, Urvi A. Shah, Aditi Shastri, Erik Guillen, Alejandro Sica, Gregoire Lauvau, Murali Janakiram, Paul D. Kassner

Blood (2024) 144 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2024-210385

Published: 2024

Journal Articles

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

John Yan, Josette Kamel, Amit Verma, Eric J. Feldman, Dennis L Cooper, Lauren Shapiro, Ridhi Gupta, Nishi Shah, Noah Kornblum, David Levitz, R. Alejandro Sica, Kira Gritsman, Aditi Shastri, Ioannis Mantzaris, Mendel Goldfinger, Marina Konopleva

Blood (2024) 144 (Supplement 1): 5966.

https://doi.org/10.1182/blood-2024-212222

Published: 2024

Journal Articles

Cigarette Smoking Is Associated with Worse Prognosis in MDS and Causes Inflammation and Hematopoietic Alterations in Murine Models

Tanya Verma, Divij Verma, Srabani Sahu, Kith Pradhan, Sakshi Jasra, Seyedeh Shareh Dehghani, Hui Zhang, Mason Spodek, Ritesh Aggarwal, Amit Verma, Dean Hosgood, Aditi Shastri, Yiyu Zou

Blood (2024) 144 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2024-204251

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Neurotoxicity of Axicabtagene Ciloleucel in an Ethnically Diverse, Real-World Cohort

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

Cigarette Smoking Is Associated with Worse Prognosis in MDS and Causes Inflammation and Hematopoietic Alterations in Murine Models

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only